The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aceso Company Pte. Ltd.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Singapore-based Aceso Company Pte. Ltd., a former promoter of HealthCare Global Enterprises (HCG), sold 7.19 crore equity shares (~51.59% of total share capital) on May 30, 2025 through an off-market deal. Before the sale, Aceso held 8.41 crore shares (60.35%) in HCG; after the sale, its holding dropped to 1.22 crore shares (~8.76%). The transaction was executed under a share purchase agreement dated February 23, 2025 involving Hector Asia II Pte. Ltd. and KIA EBT II Scheme I. As a result of the sale, Aceso will be reclassified from a 'promoter' to a 'public' shareholder of the company.
This is a major promoter exit — HCG loses its largest controlling shareholder and the promoter group stake falls well below 50%. The change in control could shift strategic direction, governance, and majority ownership to the new buyers (Hector Asia / KIA), which may materially affect stock price and investor sentiment in the short term.